We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bayer Ord | LSE:BYR | London | Ordinary Share | DE000BAY0017 | REG SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 55.93 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:8962P Bayer AG 18 September 2003 Document Dated 17 September 2003 U.S. District Court Finds in Favor of Bayer Class action certification denied in Baycol litigation Leverkusen, Germany - Bayer said today that it is pleased that the Federal District Court in Minneapolis, Minnesota found in favor of the company and denied plaintiffs motion to certify a nationwide class action in the Baycol litigation. Bayer opposed certification of a nationwide class for Baycol. The company argued that certification of a class action was not appropriate because the claims of the possible class members involve too many diverse and individual issues. Some of these include differences in state law, medical histories, Baycol dosages and Baycol use with other drugs. In addition, Bayer believes that a class action would have proven to be unmanageable. Bayer will continue its strategy of analyzing the specific circumstances of each case and the nature of each claim. It will also continue to pursue its policy of trying to agree on fair compensation for anyone who experienced serious side effects from Baycol on its own initiative and without acknowledging any legal liability. Bayer has successfully settled more than 1342 cases in the United States to date. In cases where an examination of the facts indicates that Baycol played no part in the patient's medical situation, or where a settlement is not achieved, Bayer will continue to defend itself vigorously. Bayer believes this is the most fair and reasonable manner in which to handle the litigation. Bayer AG. Investor Relations contacts: Dr. Alexander Rosar (+49-214-30-81013) Dr. Juergen Beunink (+49-214-30-65742) Peter Dahlhoff (+49-214-30-33022) Judith Nestmann (+49-214-30-66836) Forward-looking statements This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward- looking statements or to conform them to future events or developments. This information is provided by RNS The company news service from the London Stock Exchange END STRKGGMLNRDGFZG
1 Year Bayer Ord Chart |
1 Month Bayer Ord Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions